<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34003459</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1179-1934</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>35</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>CNS drugs</Title>
          <ISOAbbreviation>CNS Drugs</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status.</ArticleTitle>
        <Pagination>
          <StartPage>643</StartPage>
          <EndPage>653</EndPage>
          <MedlinePgn>643-653</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40263-021-00825-w</ELocationID>
        <Abstract>
          <AbstractText>Viloxazine has a long history of clinical use in Europe as an antidepressant, and has recently been repurposed into an extended-release form for the treatment of attention-deficit/hyperactivity disorder in the USA. An immediate-release formulation was approved for the treatment of depression in the UK in 1974, and was subsequently marketed there and in several European countries for 30 years with no major safety concerns. In contrast to first-generation antidepressants (e.g., tricyclic antidepressants, monoamine oxidase inhibitors), viloxazine was associated with a relatively low risk for cardiotoxicity. Gastrointestinal symptoms were the most commonly reported side effects. The therapeutic effects of viloxazine are thought to be primarily the result of its action as a norepinephrine reuptake inhibitor, although in vitro and preclinical in vivo animal data suggest that viloxazine may also impact the serotoninergic system. This review summarizes the evolving knowledge of viloxazine based on information from previously published preclinical and clinical investigations, and acquired unpublished historical study reports from both open-label and blinded controlled clinical trials. We review the chemical properties, mechanism of action, safety, and tolerability across these studies, and discuss the contemporary rationale for the development of this agent as an extended-release oral formulation for the treatment of attention-deficit/hyperactivity disorder.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Findling</LastName>
            <ForeName>Robert L</ForeName>
            <Initials>RL</Initials>
            <AffiliationInfo>
              <Affiliation>VCU Department of Psychiatry, 501 North 2nd Street, Richmond, VA, 23298-0308, USA. Robert.Findling@vcuhealth.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Candler</LastName>
            <ForeName>Shawn A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nasser</LastName>
            <ForeName>Azmi F</ForeName>
            <Initials>AF</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schwabe</LastName>
            <ForeName>Stefan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Chungping</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Garcia-Olivares</LastName>
            <ForeName>Jennie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Neal</LastName>
            <ForeName>Welton</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals, Inc., Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Newcorn</LastName>
            <ForeName>Jeffrey H</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Psychiatry and Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>CNS Drugs</MedlineTA>
        <NlmUniqueID>9431220</NlmUniqueID>
        <ISSNLinking>1172-7047</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018759">Adrenergic Uptake Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5I5Y2789ZF</RegistryNumber>
          <NameOfSubstance UI="D014745">Viloxazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018759" MajorTopicYN="N">Adrenergic Uptake Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002493" MajorTopicYN="N">Central Nervous System Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014745" MajorTopicYN="N">Viloxazine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Azmi F. Nasser, Stefan Schwabe, Chungping Yu, Jennie Garcia-Olivares, and Welton O’Neal are employees of Supernus Pharmaceuticals, Inc. At the time of this work, Shawn A. Candler was an employee of Supernus Pharmaceuticals, Inc. Robert L. Findling receives or has received research support, acted as a consultant and/or has received honoraria from Acadia, Adamas, Aevi, Afecta, Akili, Alkermes, Allergan, American Academy of Child &amp; Adolescent Psychiatry, American Psychiatric Press, Arbor, Axsome, Daiichi-Sankyo, Emelex, Gedeon Richter, Genentech, Idorsia, Intra-Cellular Therapies, Kempharm, Luminopia, Lundbeck, MedAvante-ProPhase, Merck, MJH Life Sciences, National Institutes of Health, Neurim, Otsuka, PaxMedica, PCORI, Pfizer, Physicians Postgraduate Press, Q BioMed, Receptor Life Sciences, Roche, Sage, Signant Health, Sunovion, Supernus Pharmaceuticals, Syneos, Syneurx, Takeda, Teva, Tris, and Validus. In the past year, Jeffrey H. Newcorn is/has been an advisor and/or consultant for Adlon Therapeutics, Arbor, Corium, Eisai, Medice, Myriad Neuroscience, NLS, OnDosis, Rhodes, Shire/Takeda, and Supernus. He has received research support from the National Institute on Drug Abuse, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Otsuka, Shire, and Supernus. He also has received speaker fees from Shire/Takeda for disease-state presentations, and served as a consultant for the US National Football League.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>12</Hour>
          <Minute>25</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34003459</ArticleId>
        <ArticleId IdType="pmc">PMC8219567</ArticleId>
        <ArticleId IdType="doi">10.1007/s40263-021-00825-w</ArticleId>
        <ArticleId IdType="pii">10.1007/s40263-021-00825-w</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Mallion KB, Todd AH, Turner RW, Bainbridge JG, Greenwood DT, Madinaveitia J, et al.  2-(2-Ethoxyphenoxymethyl)tetrahydro-1,4-oxazine hydrochloride, a potential psychotropic agent. Nature. 1972;238:157–158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4558457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinder RM, Brogden RN, Speight TM, Avery GS. Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1977;13:401–421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">324751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Renfordt E, Busch H, Fähndrich E, Müller-Oerlinghausen B. Studies on a novel antidepressant (viloxazin) by means of time-series analysis of TV data. Arzneimittelforschung. 1976;26(6):1114–1116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">786309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marsh W.  Viloxazine. In: Enna SJ, Bylund DB, editors. xPharm: the comprehensive pharmacology reference. Amsterdam: Elsevier Inc; 2007. </Citation>
        </Reference>
        <Reference>
          <Citation>National Center for Biotechnology Information, PubChem database. Viloxazine, CID = 5666. https://pubchem.ncbi.nlm.nih.gov/compound/Viloxazine. Accessed 17 Jan 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Mulrow CD.  Treatment of depression: newer pharmacotherapies. Rockville: Agency for Health Care Policy and Research; 1999. </Citation>
        </Reference>
        <Reference>
          <Citation>Kabes J, Dostal T, Nahunek K, Svestka J, Molcan J, Caplová T, et al.  Multicentre study with viloxazine (Vivalan®) in depressed patients. Int Pharmacopsychiatr. 1980;15:228–239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7021448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>US Food and Drug Administration. Orphan drug designations and approvals. Catatrol. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=2384. Accessed 30 Apr 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Williams D.  Antidepressants. In: Lemke TL, Williams DA, Roche VF, Zito SW, editors. Foye's principles of medicinal chemistry. 7. Philadelphia: Lippincott Williams &amp; Wilkins; 2013. </Citation>
        </Reference>
        <Reference>
          <Citation>Murphy JE. Vivalan: drug profile. J Int Med Res. 1975;3:122–125.</Citation>
        </Reference>
        <Reference>
          <Citation>Blackburn TP, Foster GA, Greenwood DT, Howe R. Effects of viloxazine, its optical isomers and its major metabolites on biogenic amine uptake mechanisms in vitro and in vivo. Eur J Pharmacol. 1978;52:367–374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">729646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lippman W, Pugsley TA. Effects of viloxazine, an antidepressant agent, on biogenic amine uptake mechanisms and related activities. Can J Physiol Pharmacol. 1976;54:494–509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">974878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenwood DT. Animal pharmacology of viloxazine (Vivalan) J Int Med Res. 1975;3:18–28.</Citation>
        </Reference>
        <Reference>
          <Citation>Martin IL, Baker GB, Mitchell PR. The effect of viloxazine hydrochloride on the transport of noradrenaline, dopamine, 5-hydroxytryptamine and gamma-amino-butyric acid in rat brain tissue. Neuropharmacology. 1978;17(6):421–423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">673157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7473988</ArticleId>
            <ArticleId IdType="pubmed">32943948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones RSG, Roberts MHT. Potentiation of responses to monoamines by antidepressants after destruction of monoamine afferents. Br J Pharmacol. 1979;65(3):501–510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1668645</ArticleId>
            <ArticleId IdType="pubmed">311665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones RSG, Roberts MHT. Potentiation of monoamine responses of denervated cells by a noradrenaline uptake inhibitor (viloxazine) Br J Pharmacol. 1978;62(3):403P–P404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1668201</ArticleId>
            <ArticleId IdType="pubmed">638334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cathala A, Devroye C, Drutel G, Revest JM, Artigas F, Spampinato U. Serotonin2B receptors in the rat dorsal raphe nucleus exert a GABA-mediated tonic inhibitory control on serotonin neurons. Exp Neurol. 2019;311:57–66. doi: 10.1016/j.expneurol.2018.09.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2018.09.015</ArticleId>
            <ArticleId IdType="pubmed">30257183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hall H, Sällemark M, Wedel I. Acute effects of atypical antidepressants on various receptors in the rat brain. Acta Pharmacol Toxicol (Copenh). 1984;54(5):379–384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6464782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalivas PW, Volkow N. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162:1403–1413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16055761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Volkow N, Fowler JS, Wang GJ, Swanson JM, Telang F. Dopamine in drug abuse and addiction. Arch Neurol. 2007;64(11):1575–1579.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17998440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clemow DB, Walker DJ. The potential for misuse and abuse of medications in ADHD: a review. Postgrad Med. 2014;126(5):64–81. doi: 10.3810/pgm.2014.09.2801.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3810/pgm.2014.09.2801</ArticleId>
            <ArticleId IdType="pubmed">25295651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnsten A. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J Clin Psychiatry. 2006;67:7–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16961424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnsten AF. The emerging neurobiology of attention deficit hyperactivity disorder: the key role of the prefrontal association cortex. J Pediatr. 2009;154(5):I-S43. doi: 10.1016/j.jpeds.2009.01.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpeds.2009.01.018</ArticleId>
            <ArticleId IdType="pmc">PMC2894421</ArticleId>
            <ArticleId IdType="pubmed">20596295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curatolo P, D'Agati E, Moavero R. The neurobiological basis of ADHD. Ital J Pediatr. 2010;36(1):79. doi: 10.1186/1824-7288-36-79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1824-7288-36-79</ArticleId>
            <ArticleId IdType="pmc">PMC3016271</ArticleId>
            <ArticleId IdType="pubmed">21176172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy F. The dopamine theory of attention deficit hyperactivity disorder (ADHD) Aust N Z J Psychiatry. 1991;25(2):277–283. doi: 10.3109/00048679109077746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/00048679109077746</ArticleId>
            <ArticleId IdType="pubmed">1652243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy F. Pharmacological and therapeutic directions in ADHD: specificity in the PFC. Behav Brain Funct. 2008;4:12. doi: 10.1186/1744-9081-4-12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1744-9081-4-12</ArticleId>
            <ArticleId IdType="pmc">PMC2289834</ArticleId>
            <ArticleId IdType="pubmed">18304369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swanson JM, Kinsbourne M, Nigg J, Lanphear B, Stefanatos GA, Volkow N, et al.  Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol Rev. 2007;17(1):39–59. doi: 10.1007/s11065-007-9019-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11065-007-9019-9</ArticleId>
            <ArticleId IdType="pubmed">17318414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faraone SV. The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev. 2018;87:255–270. doi: 10.1016/j.neubiorev.2018.02.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neubiorev.2018.02.001</ArticleId>
            <ArticleId IdType="pmc">PMC8063758</ArticleId>
            <ArticleId IdType="pubmed">29428394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hutson PH, Pennick M, Secker R. Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug. Neuropharmacology. 2014;87:41–50. doi: 10.1016/j.neuropharm.2014.02.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuropharm.2014.02.014</ArticleId>
            <ArticleId IdType="pubmed">24594478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hall H, Ogren SO. Effects of antidepressant drugs on histamine-H1 receptors in the brain. Life Sci. 1984;34(6):597–605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6141518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones RSG, Roberts MHT. Modification of cortical neuron responses to acetylcholine by viloxazine. J Pharm Pharmacol. 1979;31:87–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones RSG. Long-term administration of atropine, imipramine, and viloxazine alters responsiveness of rat cortical neurones to acetylcholine. Can J Physiol Pharmacol. 1980;58(5):531–535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7417880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golds PR, Przyslo FR, Strange PG. The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980;68:541–549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2044199</ArticleId>
            <ArticleId IdType="pubmed">7052344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez C, Dominiak P, Kees F, Grobecker H. Inhibition of monoamine oxidase by viloxazine in rats. Drug Res. 1986;36(1):800–803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2425816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, et al.  A phase 3, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended release) in the treatment of ADHD in school-age children. Clin Ther. 2020;42(8):1452–1466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32723670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Busse GD, et al.  Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021 doi: 10.1016/j.clinthera.2021.01.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2021.01.027</ArticleId>
            <ArticleId IdType="pubmed">33750646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Busse GD, et al. A phase 3, placebo-controlled trial of once-daily viloxazine extended-release in adolescents with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, et al.  A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD. Psychopharm Bul. 2021;51(2):43–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8146561</ArticleId>
            <ArticleId IdType="pubmed">34092822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supernus Pharmaceuticals Inc. Supernus announces positive results from phase III study for SPN-812 in adults with ADHD. 2020. https://ir.supernus.com/news-releases/news-release-details/supernus-announces-positive-results-phase-iii-study-spn-812-0. Accessed 10 May 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Bayliss PFC, Case DE. Blood level studies with viloxazine hydrochloride in man. Br J Clin Pharmacol. 1975;2:209–214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1402576</ArticleId>
            <ArticleId IdType="pubmed">1234502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pisani F, Fazio A, Spina E, Artesi C, Pisani B, Russo M, et al.  Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. Psychopharmacology. 1986;90:295–298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3097715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Case DE, Reeves PR. The disposition and metabolism of I.C.I. 58,834 (viloxazine) in humans. Xenobiotica. 1975;5(2):113–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1154799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Case DE, Illston H, Reeves PR, Shuker B, Simons P. The disposition and metabolism of I.C.I. 58,834 (viloxazine) in animals. Xenobiotica. 1975;5(2):83–111. doi: 10.3109/00498257509056096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/00498257509056096</ArticleId>
            <ArticleId IdType="pubmed">808041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>American Psychiatric Association  . Diagnostic and statistical manual of mental disorders. 5. Washington, D.C.: American Psychiatric Publishing; 2013. </Citation>
        </Reference>
        <Reference>
          <Citation>Ban TA, McEvoy JP, Wilson WH. Viloxazine: a review of the literature. Int Pharmacopsychiatr. 1980;15:118–123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7002831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bayliss PFC, Dewsbury AR, Donald JF, Harcup JW, Mayer M, Million R, et al.  A double-blind controlled trial of 'Vivalan' (viloxazine hydrochloride) and imipramine hydrochloride in the treatment of depression in general practice. J Int Med Res. 1974;2:260–264.</Citation>
        </Reference>
        <Reference>
          <Citation>Bayliss PFC, Harcup JW, Mayer M, Million R, Murphy JE, Plant B, et al.  An open study of two dose levels of ‘Vivalan’ (viloxazine hydrochloride ICI 58 834) in depression in general practice. J Int Med Res. 1974;2:253–259.</Citation>
        </Reference>
        <Reference>
          <Citation>Altamura AC, Mauri MC, Girardi T, Panetta B. Alcoholism and depression: a placebo controlled study with viloxazine. Int J Clin Pharmacol Res. 1990;10(5):293–298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2079386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bouchard JM, Strub N, Nil R. Citalopram and viloxazine in the treatment of depression by means of slow drop infusion: a double-blind comparative trial. J Affect Disord. 1997;46:51–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9387086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moizeszowicz J, Subirá S. Controlled trial of nomifensin (HOE 984) and viloxazine in the treatment of depression in the elderly. J Clin Pharmacol. 1977;17(1):81–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">319120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brosnan RD, Busby AM, Holland RP. Cases of overdosage with viloxazine hydrochloride (Vivalan) J Int Med Res. 1976;4:83–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1026544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corona G, Frattini P, Cucchi M, Santagostino G, Schinelli S, Zerbi F, et al.  Viloxazine in depressed women: clinical response and cardiovascular effects. Int J Clin Pharmacol Ther Toxicol. 1987;25(6):322–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3623737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasser A, Faison SL, Liranso T, Adewole T, Busse GD, Fava M, et al.  Evaluation of the effect of SPN-812 (viloxazine extended release) on QTc interval in healthy adults. J Clin Psychiatry. 2020;81(6):e1–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33049804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bayliss PFC, Duncan SM. The clinical pharmacology of viloxazine hydrochloride: a new anti-depressant of novel chemical structure. Br J Clin Pharmacol. 1974;1:431–437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1402474</ArticleId>
            <ArticleId IdType="pubmed">22454923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner P, Bayliss PFC, Ghose K. Clinical pharmacoolgy of viloxazine (Vivalan) J Int Med Res. 1975;3:41–47.</Citation>
        </Reference>
        <Reference>
          <Citation>Meldrum B, Anlezark G, Adam H, Greenwood D. Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: pharmacological and pharmacokinetic studies in rodents and the epileptic baboon. Psychopharmacology. 1982;76(3):212–217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6808538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edwards JG, Glen-Bott M. Does viloxazine have epileptogenic properties? J Neurol Neurosurg Psychiatry. 1984;47:960–964.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1027998</ArticleId>
            <ArticleId IdType="pubmed">6434699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pisani F, Fazio A, Oteri G, Perucca E, Russo M, Trio R, et al.  Carbamazepine-viloxazine interaction in patients with epilepsy. J Neurol Neurosurg Psychiatry. 1986;49:1142–1145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1029047</ArticleId>
            <ArticleId IdType="pubmed">3783175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy JE. Vivalan: drug profile. J Int Med Res. 1975;3:112–115.</Citation>
        </Reference>
        <Reference>
          <Citation>Březinová V, Adam K, Chapman K, Oswald I, Thomson J. Viloxazine, sleep, and subjective feelings. Psychopharmacology. 1977;55:121–128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">202985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirby M, Turner P. Some preliminary observations on ICI 58 834, a new psychotropic agent, in man. Br J Clin Pharmacol. 1973;1(2):169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1402456</ArticleId>
            <ArticleId IdType="pubmed">22454905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry. 1999;46:1234–1242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10560028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banerjee E, Nandagopal K. Does serotonin deficit mediate susceptibility to ADHD? Neurochem Int. 2015;82:52–68. doi: 10.1016/j.neuint.2015.02.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuint.2015.02.001</ArticleId>
            <ArticleId IdType="pubmed">25684070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oades R. The role of the serotonin system in ADHD. Expert Rev Neurother. 2007;7:1357–1374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17939772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD) Ann Pharmacother. 2014;48(2):209–225. doi: 10.1177/1060028013510699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1060028013510699</ArticleId>
            <ArticleId IdType="pubmed">24259638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viggiano D, Ruocco LA, Arcieri S, Sadile AG. Involvement of norepinephrine in the control of activity and attentive processes in animal models of attention deficit hyperactivity disorder. Neural Plast. 2004;11(1–2):133–149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2565437</ArticleId>
            <ArticleId IdType="pubmed">15303310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson JK, Liranso T, Saylor K, Tulloch G, Adewole T, Schwabe S, et al.  A phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (extended-release viloxazine) in children with ADHD. J Atten Disord. 2020;24(2):348–358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6939319</ArticleId>
            <ArticleId IdType="pubmed">30924702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Catala-Lopez F, Hutton B, Nunez-Beltran A, Page MJ, Ridao M, Macias Saint-Gerons D, et al.  The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PLoS ONE. 2017;12(7):e0180355. doi: 10.1371/journal.pone.0180355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0180355</ArticleId>
            <ArticleId IdType="pmc">PMC5507500</ArticleId>
            <ArticleId IdType="pubmed">28700715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortese S. Pharmacologic treatment of attention deficit-hyperactivity disorder. N Engl J Med. 2020;383(11):1050–1056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32905677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederman J, Spencer T, Wilens T. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2004;7(1):77–97. doi: 10.1017/S1461145703003973.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S1461145703003973</ArticleId>
            <ArticleId IdType="pubmed">14733627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995;152:1652–1658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7485630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilens T. Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry. 2004;65:38–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15046534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soutullo C, DelBello MP, Ochsner JE, McElroy SL, Taylor SA, Strakowski SM, et al.  Severity of bipolarity in hospitalized manic adolescents with history of stimulant or antidepressant treatment. J Affect Disord. 2002;70:323–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12128245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corkum P, Moldofsky H, Hogg-Johnson S, Humphries T, Tannock R. Sleep problems in children with attention-deficit/hyperactivity disorder: impact of subtype, comorbidity, and stimulant medication. J Am Acad Child Adolesc Psychiatry. 1999;38(10):1285–1293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10517062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Briars L, Todd T. A review of pharmacological management of attention-deficit-hyperactivity disorder. J Pediatr Pharmacol Ther. 2016;21(3):192–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4956327</ArticleId>
            <ArticleId IdType="pubmed">27453697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mydayis (mixed salts of a single-entity amphetamine product) extended-release [package insert]. Lexington: Shire US, Inc.; 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Adhansia XR (methylphenidate hydrochloride) extended-release [package insert]. Stamford: Purdue Pharma L.P.; 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35(4):409–432. doi: 10.1097/00004583-199604000-00008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00004583-199604000-00008</ArticleId>
            <ArticleId IdType="pubmed">8919704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Treuer T, Gau SS, Mendez L, Montgomery W, Monk JA, Altin M, et al.  A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. J Child Adolesc Psychopharmacol. 2013;23(3):179–193. doi: 10.1089/cap.2012.0093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2012.0093</ArticleId>
            <ArticleId IdType="pmc">PMC3696926</ArticleId>
            <ArticleId IdType="pubmed">23560600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molife C, Bernauer MJ, Farr AM, Haynes VS, Kelsey D. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations. Postgrad Med. 2012;124(5):7–22. doi: 10.3810/pgm.2012.09.2586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3810/pgm.2012.09.2586</ArticleId>
            <ArticleId IdType="pubmed">23095422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kollins SH, Jain R, Brams M, Segal S, Findling RL, Wigal SB, et al.  Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011;127(6):e1406–e1413. doi: 10.1542/peds.2010-1260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2010-1260</ArticleId>
            <ArticleId IdType="pmc">PMC3387872</ArticleId>
            <ArticleId IdType="pubmed">21555501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adler LA, Reingold LS, Morrill MS, Wilens TE. Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep. 2006;8:409–415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16968624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71(6):754–763. doi: 10.4088/JCP.08m04902pur.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4088/JCP.08m04902pur</ArticleId>
            <ArticleId IdType="pubmed">20051220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez-Raga J, Knecht C, Szerman N, Martinez MI. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS Drugs. 2013;27(1):15–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23160939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sayer GR, McGough JJ, Levitt J, Cowen J, Sturm A, Castelo E, et al.  Acute and long-term cardiovascular effects of stimulant, guanfacine, and combination therapy for attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2016;26(10):88–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5178010</ArticleId>
            <ArticleId IdType="pubmed">27483130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schelleman H, Bilker WB, Kimmel SE, Daniel GW, Newcomb C, Guevara JP, et al.  Amphetamines, atomoxetine and the risk of serious cardiovascular events in adults. PLoS ONE. 2013;8(1):e52991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3559703</ArticleId>
            <ArticleId IdType="pubmed">23382829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henderson TA, Hartman K. Aggression, mania, and hypomania induction associated with atomoxetine. Pediatrics. 2004;114(3):895–896.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15342872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horrigan JP, Barnhill LJ. Guanfacine and secondary mania in children. J Affect Disord. 1999;54(3):309–314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10467976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bangs ME, Tauscher-Wisniewski S, Polzer J, Zhang S, Acharya N, Desaiah D, et al.  Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry. 2008;47(2):209–218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18176331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenwood DT. Viloxazine and neurotransmitter function. Adv Biochem Psychopharmacol. 1982;31:287–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6282059</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
